PROTEUS Substudy Reports 63% of Prostate Cancer Patients Avoid Recurrence With Combination Therapy
A substudy of the PROTEUS trial found that 63% of men who received the hormone therapy apalutamide plus androgen-deprivation therapy before and after surgery were free of tracked cancer-related events at three years, compared with 41% of men who had surgery alone.
Read Full Article: https://www.naturalnews.com/2026-10-29-proteus-substudy-prostate-cancer-patients-combination-therapy.html
